Volume 12 Number 7/8 July/August 2011
This issue leads with the most important and exciting research from the IAS conference in Rome and the 3rd International Workshop on HIV Pediatrics immediately preceding it. Our reports in this issue include an overview of the conference in the Introduction.
We conclude our reports form the BHIVA and CROI meetings this year and include exciting news on treatment access due to Gilead entering an agreement with the Medicines Patent Pool.
New recently approved drugs (in the USA) include the new NNRTI rilpivirine and a new triple drug fixed-dose combination of rilpivirine/tenofovir/FTC.
We also launched the i-Base/TAG 2011 pipeline report in Rome as a supplement to HTB that updates the pipeline development of all important drugs, diagnostics and treatment strategies for HIV, hepatitis and TB.